Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Marie-Christine
Marie-Christine Bissery, Vitry Sur Seine FR
| Patent application number | Description | Published |
|---|---|---|
| 20090023656 | Combination Comprising Combretastatin and Anticancer Agents - This invention relates to therapeutic combinations comprising VEGF Trap and a stilbene derivative, and to methods for treatment of cancer comprising administration of such combinations. | 01-22-2009 |
| 20090196869 | ANTITUMOR COMBINATIONS CONTAINING TAXANE DERIVATIVES - The disclosure relates to pharmaceutical combinations comprising acetylcyclopropyl docetaxel and a monoclonal antibody against ErbB2, and to methods of use thereof. | 08-06-2009 |
| 20110054035 | Combination Comprising Combretastatin and Anticancer Agents - This invention relates to therapeutic combinations comprising VEGF Trap and a stilbene derivative, and to methods for treatment of cancer comprising administration of such combinations. | 03-03-2011 |
| 20110263522 | ANTITUMOUR COMPOSITIONS CONTAINING TAXANE DERIVATIVES - Antitumor combinations comprising a taxane and at least one antibiotic for treating neoplastic diseases are described. | 10-27-2011 |
Marie-Christine Bissery, Charenton Le Pont FR
| Patent application number | Description | Published |
|---|---|---|
| 20090285841 | ANTITUMOR COMBINATIONS CONTAINING A VEGF-INHIBITING AGENT AND 5FU OR A DERIVATIVE THEREOF - This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations. | 11-19-2009 |
| 20100160233 | ANTITUMOUR COMBINATIONS CONTAINING A VEGF INHIBITING AGENT AND IRINOTECAN - Disclosed are antitumor combinations of VEGF inhibitors with Irinotecan and the use thereof in the treatment of neoplastic diseases. | 06-24-2010 |
Marie-Christine Brezak Pannetier, Antony FR
| Patent application number | Description | Published |
|---|---|---|
| 20090082345 | BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS - The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S. In accordance with the invention, the compounds of general formula (I) can in particular be used for preparing a medicine for cancer treatment. | 03-26-2009 |
| 20090131428 | BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS - The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S. In accordance with the invention, the compounds of general formula (I) can in particular be used for preparing a medicine for cancer treatment. | 05-21-2009 |
| 20090137596 | G-PROTEIN INHIBITOR - A subject of the invention is a product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent for a therapeutic use which is simultaneous, separate or spread over time in the treatment of cancer. | 05-28-2009 |
| 20090253685 | Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent - A subject of the invention is a product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent for a therapeutic use which is simultaneous, separate or spread over time in the treatment of cancer. | 10-08-2009 |
| 20100173910 | TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS - The present invention relates to triaminopyrimidine derivatives of formula (I) | 07-08-2010 |
Marie-Christine Canavaggio, Vienna AT
| Patent application number | Description | Published |
|---|---|---|
| 20080221032 | Factor VIIa-Polysialic Acid Conjugate Having Prolonged In Vivo Half-Life - The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma. | 09-11-2008 |
| 20110064714 | FACTOR VIIA-POLYSIALIC ACID CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE - The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma. | 03-17-2011 |
Marie-Christine Champomier-Verges, Sceaux FR
| Patent application number | Description | Published |
|---|---|---|
| 20110172112 | Combination of Marker Genes for Characterizing a Lactobacillus Sakei Strain - The present invention relates to a new combination of marker genes for characterizing a | 07-14-2011 |
Marie-Christine Dubs-Poterszman, Wolfisheim FR
| Patent application number | Description | Published |
|---|---|---|
| 20080311608 | Antagonist of the oncogenic activity of the protein MDM2, and use thereof in the treatment of cancers - The present invention relates to the utilization of a compound capable of antagonizing at least partially the oncogenic activity of the protein Mdm2 for the preparation of a pharmaceutical composition intended more particularly to a treatment of cancers with no p53 context. It further relates to the viral vector comprising a nucleic acid sequence coding for a compound capable of inhibiting at least partially the oncogenic activity of the protein Mdm2, and to a corresponding pharmaceutical composition. | 12-18-2008 |
Marie-Christine HjertÉn, Uppsala SE
| Patent application number | Description | Published |
|---|---|---|
| 20100330141 | PRODUCT FOR ABSORPTION PURPOSES - A product for absorption purposes comprises a water insoluble support matrix substituted with a hydrophobic entity and a positively charged entity. The hydrophobic entity comprises di-alkyl carbamoyl chloride (DACC) and the positively charged entity comprises polyethyleneimine (PEI). The product is capable of removing microorganisms, including viruses, from air and liquid. Methods for manufacturing the product and uses and applications of the product are also presented. | 12-30-2010 |
Marie-Christine HjertÉn, Uppsala SE
| Patent application number | Description | Published |
|---|---|---|
| 20100330141 | PRODUCT FOR ABSORPTION PURPOSES - A product for absorption purposes comprises a water insoluble support matrix substituted with a hydrophobic entity and a positively charged entity. The hydrophobic entity comprises di-alkyl carbamoyl chloride (DACC) and the positively charged entity comprises polyethyleneimine (PEI). The product is capable of removing microorganisms, including viruses, from air and liquid. Methods for manufacturing the product and uses and applications of the product are also presented. | 12-30-2010 |
Marie-Christine Jaulent, Vanves FR
| Patent application number | Description | Published |
|---|---|---|
| 20090055378 | SYSTEMS AND METHODS FOR PROVIDING IMPROVED ACCESS TO PHAMACOVIGILANCE DATA - A system and method for browsing a pharmacovigilance database with a graphical representation that shows relationships between medical terms may include providing access to a plurality of medical terminologies and mapping medical terms of the plurality of terminologies to a searchable database by using a semantic network to relate the medical terms of the different terminologies. The system and method may further include providing a graphical user interface that enables graphical navigation of the plurality of terminologies, enables display of a mapping between a first medical term from a first medical terminology to a second medical term from a second medical terminology, and enables coding of pharmacovigilance reports using medical terms of the second terminology based on a description provided using medical terms of the first terminology. | 02-26-2009 |
Marie-Christine Kieffer-Meyer, Mont Saint Aignan FR
| Patent application number | Description | Published |
|---|---|---|
| 20110195452 | SET OF SEQUENCES FOR TARGETING EXPRESSION AND CONTROL OF THE POST-TRANSLATIONAL MODIFICATION OF A RECOMBINANT POLYPEPTIDE - The present invention provides new tools useful for controlling the post-translational modifications of recombinant polypeptides. These tools are particular signal peptides allowing the targeting of recombinant polypeptides during their synthesis in a host cell to specific sub-cellular compartments and a specific designing of said recombinant polypeptides within said sub-cellular compartments. These signal peptides are SEQ ID no 1 to SEQ ID no 31 disclosed herein. The present invention relates therefore also to a process for producing a recombinant polypeptide, in particular to a post-translationally modified polypeptide comprising the steps of transfecting or transforming a cell with at least one numleic acid vector encoding a recombinant protein which is the polypeptide before being post-translationally modified or a recombinant protein different to said polypeptide, said recombinant protein comprising a peptide signal according to the present invention; growing the transfected cell; and harvesting the post-translationally modified polypeptide; wherein, when said recombinant protein is different to said polypeptide, the method also comprises a step of transfecting said cell with at least one vector encoding said polypeptide. The present invention allows advantageously, for example, to increase the yield of production of recombinant polypeptides, to prevent immunogenicity if recombinant polypeptides and to obtain therapeutically active recombinant polypeptides that are the exact copy of their natural counterpart. This invention relates particularly to the field of reorientation of plants made pharmaceuticals (PMP). | 08-11-2011 |
Marie-Christine Multon, Versailles FR
| Patent application number | Description | Published |
|---|---|---|
| 20120009604 | USE OF GRF1 PROTEIN FOR SCREENING MOLECULES - The invention concerns the use of whole or part of the GRF1 protein, or of cells expressing whole or part of the GRF1 protein, in methods for detecting compounds for preventing and/or treating pathologies or disorders of the central nervous system involving neuronal death, such as apoptosis, or related to leptin metabolism. The pathologies of the central nervous system are in particular cerebral ischemia, Parkinson's disease or Alzheimer's disease. | 01-12-2012 |
Marie-Christine Secretin, Blonay CH
| Patent application number | Description | Published |
|---|---|---|
| 20090142442 | GUT MICROBIOTA IN INFANTS - The use of a whey predominant protein source and lactose in the manufacture of a nutritional composition for promoting the development of an early bifidogenic intestinal microbiota in infants fed with the nutritional composition wherein the nutritional composition has a protein content of less than 2.1 g protein/100 kcal and a phosphorus content of less than 40 mg/100 kcal. | 06-04-2009 |
Marie-Christine Wolf, St. Louis FR
| Patent application number | Description | Published |
|---|---|---|
| 20100209480 | GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS - The present invention relates to a pharmaceutical oral fixed dose combination comprising | 08-19-2010 |